Dynavax Technologies Corporation (DVAX) : On Wednesday, The money flowed into the Dynavax Technologies Corporation (DVAX) stock with an uptick to downtick ratio was recorded at 3.81. Transactions worth $5.39 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $1.42 million. The total money flow into the stock was $3.98 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $3.91 million of block transactions on upticks. The total money flow in block trades was $3.91 million. In terms of price action, Dynavax Technologies Corporation (DVAX) traded down $0.05 during the session at $10.87. Compared to the previous days closing, the stock was down only by -0.41%. For the week, the stock is -4.78%, over previous weeks closing.
Dynavax Technologies Corporation has lost 4.54% in the last five trading days and dropped 31.61% in the last 4 weeks. Dynavax Technologies Corporation has dropped 22.48% during the last 3-month period . Year-to-Date the stock performance stands at -53.89%.
Dynavax Technologies Corporation (DVAX) : The consensus on Dynavax Technologies Corporation (DVAX) based on 3 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Dynavax Technologies Corporation (NASDAQ:DVAX): The stock opened at $10.89 and touched an intraday high of $11.34 on Wednesday. During the day, the stock corrected to an intraday low of $10.67, however, the bulls stepped in and pushed the price higher to close in the green at $11.14 with a gain of 2.11% for the day. The total traded volume for the day was 2,006,501. The stock had closed at $10.91 in the previous trading session.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.